Latest from ObNowa.

New global pharmaceutical development company, headquartered in Poland, unites hair-growth science originating from Aneira Pharma with neurotoxin programs building on Object Pharma expertise.

Published industry analyses project sustained double-digit growth in aesthetic neuromodulation. Comparability-based entry may reshape access and pricing across European markets.

Demand for in-clinic hair and brow treatments continues to expand. The science of the follicle niche is opening new development routes.